Citi analyst Robyn Karnauskas opened a 30 day catalyst watch for Epizyme in anticipation of an FDA decision on the partial hold on Tazemetostat. In the best case scenario, the analyst expects the partial hold to be lifted at the end of the 30 day period without any further delay. She notes that We note that Tazemetostat has been investigated in multiple indications, administered to 750 patients, and shown an overall positive safety profile with only a single case of secondary lymphoma. The analyst keeps a Buy rating on Epizyme.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.